Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

January 1, 2011

View Archives Issues

  • Great results from iPrEx study add to trifecta of good news on prevention

    Close on the heels of the first positive findings reported in microbicides and vaccine research ventures, the iPrEx study has shown that a pre-exposure prophylaxis (PrEP) combination drug demonstrates 44% additional protection from HIV infection.
  • Legislative barriers hinder progress in opt-out testing

    Opt-out HIV testing goals by the Centers for Disease Control and Prevention (CDC) of Atlanta, GA, would have greater success if states were to reduce legislative barriers, an expert says.
  • Q&A on one-minute HIV test approval

    [Editor's note: With the recent news that the U.S. Food and Drug Administration (FDA) has approved a new HIV test that obtains results within one minute, domestic HIV testing and prevention strategies have a new tool to employ. AIDS Alert asked Philip Bligh, president of bioLytical Laboratories in Vancouver, British Columbia and Chicago, IL, to answer questions in writing about his company's INSTI test. His responses are shown in this Q&A story]:
  • Once daily pill yields higher ART adherence

    Even HIV-infected individuals who have the greatest challenges in adhering to their antiretroviral (ART) can achieve high adherence on a regimen of one pill taken daily, research shows.
  • Abstract & Commentary: A key host response to HIV infection

    The genomics of resistance to immunodeficiency virus (GRIV) Cohort was established in France in 1995 to generate a large database for genetic studies to identify host genes associated with rapid progression and long-term non-progression to AIDS.
  • Don't test, don't know: The danger of denial

    Results of a new analysis of 21 major U.S. cities from the Centers for Disease Control and Prevention indicate approximately one in five (19%) men who have sex with men (MSM) in a study is infected with HIV, and nearly half (44%) of those men are unaware of their infection.
  • FDA Notifications

    On Nov. 10, 2010, the Food and Drug Administration (FDA) approved tessamorelin (Egrifta®) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs (visceral body fat).
  • CDC issues STD treatment update

    The Centers for Disease Control and Prevention has released new guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs).